Drs. Koshkin and Nizam discuss how a longer treatment-free interval may predict benefit from pembrolizumab rechallenge. Drs. Koshkin and Nizam break down recent research on pembro in patients with la/mUC who responded to first-course pembro. Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption. Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals. Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options. Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance. Dr. Hong reviews relevant key findings from clinical trials for oligometastatic disease. Dr. Hong reviews the criteria used to determine which patients may benefit from MDT. Dr. Chu highlights how PSMA PET is transforming perioperative prostate cancer care, including improving surgical precision. CA9 imaging and ZIRCON data offer new insight into managing small renal masses and supporting personalized kidney cancer care Drs. Joyce and Chang discuss diagnostic strategies and future innovations in managing small renal masses. Dr. Koshkin highlights emerging data on Nectin-4–targeted imaging and radiopharmaceuticals in urothelial cancer. Dr. Koshkin shares an overview of FAP-targeted theranostics, including UCSF-led studies showing FAP PET imaging’s ability. Dr. Grivas provides perspective of the long-term outcomes from the JAVELIN Bladder 100 trial as pertaining to older patients. Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy. Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease. Dr. Antonarakis discusses the differences between PARP1 mRNA expression and other biomarkers used for risk stratification. Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment. Dr. Hope evaluates PSMA PET vs SPECT imaging for tracking therapy response in prostate cancer. Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.